A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Verastem, Inc.
Eli Lilly and Company
Eli Lilly and Company
Incyte Corporation
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Novartis
AstraZeneca
BeiGene
M.D. Anderson Cancer Center
Checkpoint Therapeutics, Inc.
Phanes Therapeutics
Jiangsu Hansoh Pharmaceutical Co., Ltd.
SCRI Development Innovations, LLC
Nektar Therapeutics
Eli Lilly and Company
NextCure, Inc.
AbbVie
Mereo BioPharma
AbbVie
Clovis Oncology, Inc.
M.D. Anderson Cancer Center
AstraZeneca
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
UNC Lineberger Comprehensive Cancer Center
CanBas Co. Ltd.
Stanford University
Millennium Pharmaceuticals, Inc.